DrugPatentWatch Database Preview
Synthon Pharms Company Profile
» See Plans and Pricing
What is the competitive landscape for SYNTHON PHARMS, and when can generic versions of SYNTHON PHARMS drugs launch?
SYNTHON PHARMS has twelve approved drugs.
There is one US patent protecting SYNTHON PHARMS drugs. There are three tentative approvals on SYNTHON PHARMS drugs.
There are five patent family members on SYNTHON PHARMS drugs in five countries and thirty-four supplementary protection certificates in ten countries.
Summary for Synthon Pharms
| International Patents: | 5 |
| US Patents: | 1 |
| Tradenames: | 10 |
| Ingredients: | 10 |
| NDAs: | 12 |
Drugs and US Patents for Synthon Pharms
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synthon Pharms | RISPERIDONE | risperidone | TABLET;ORAL | 078187-002 | Oct 22, 2009 | DISCN | No | No | Start Trial | Start Trial | |||||
| Synthon Pharms | FLUVOXAMINE MALEATE | fluvoxamine maleate | TABLET;ORAL | 075899-001 | Jan 17, 2001 | DISCN | No | No | Start Trial | Start Trial | |||||
| Synthon Pharms | AMLODIPINE BESYLATE | amlodipine besylate | TABLET, ORALLY DISINTEGRATING;ORAL | 022026-003 | Sep 27, 2007 | DISCN | No | No | 6,828,339 | Start Trial | Y | Start Trial | |||
| Synthon Pharms | BICALUTAMIDE | bicalutamide | TABLET;ORAL | 077973-001 | Jul 6, 2009 | DISCN | No | No | Start Trial | Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Premature patent expirations for SYNTHON PHARMS
Expiration due to failure to pay maintenance fee
| Patent Number | Expiration Date |
|---|---|
| Start Trial | Start Trial |
International Patents for Synthon Pharms Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 03043635 | Start Trial |
| Australia | 2002343257 | Start Trial |
| European Patent Office | 1448197 | Start Trial |
| Argentina | 037565 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Synthon Pharms Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0720599 | C300172 | Netherlands | Start Trial | PRODUCT NAME: EZETIMIBE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, EN SIMVASTATINE; NAT. REGISTRATION NO/DATE: RVG 30927RVG 30928RVG 30929RVG 30930 2004221122; FIRST REGISTRATION: 58874.00.0058874.01.0058874.02.0058874.03.0058878.00.0058878.01.0058878.02.0058878.03.0058866.00.0058866.01.0058866.02.0058866.03.0058870.00.0058870.01.0058870.02.0058870.03.00 2004020402 |
| 1915993 | 92315 | Luxembourg | Start Trial | PRODUCT NAME: COMBINAISON COMPRENANT ALISKIREN,OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLE,ET AMLODIPINE,OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLE |
| 0443983 | 2007C/043 | Belgium | Start Trial | PRODUCT NAME: AMLODIPINE ET VALSARTAN; NATL. REGISTRATION NO/DATE: EU/1/06/370/001 20070118; FIRST REGISTRATION: CH 57771 20061222 |
| 1915993 | C300625 | Netherlands | Start Trial | PRODUCT NAME: COMBINATIE BEVATTENDE ALISKIREN, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, EN AMLODIPINE, OF EEN FARMACEUATISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/11/686/001-056 20110414 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
